MeSH term
Frequency | Condition_Probility | Animals | 115 | 0.0 |
DNA Damage | 2 | 0.0 |
Gene Expression | 3 | 0.0 |
Humans | 245 | 0.0 |
Aged | 32 | 0.0 |
Amino Acid Sequence | 19 | 0.0 |
Female | 87 | 0.0 |
Male | 127 | 0.0 |
Molecular Sequence Data | 25 | 0.0 |
Mutation | 2 | 0.0 |
Point Mutation | 2 | 0.0 |
Receptor, Angiotensin, Type 2 | 17 | 22.0 |
Research Support, U.S. Gov't, P.H.S. | 70 | 0.0 |
Signal Transduction | 5 | 0.0 |
Angiotensin II/*metabolism | 12 | 25.0 |
Dimerization | 2 | 0.0 |
Dose-Response Relationship, Drug | 31 | 0.0 |
Enzyme Activation | 6 | 0.0 |
JNK Mitogen-Activated Protein Kinases | 2 | 0.0 |
Mitogen-Activated Protein Kinase 1/metabolism | 3 | 0.0 |
Mitogen-Activated Protein Kinase 3 | 4 | 0.0 |
Protein Binding | 13 | 0.0 |
Rats | 46 | 0.0 |
Rats, Sprague-Dawley | 14 | 0.0 |
*Signal Transduction | 2 | 0.0 |
Time Factors | 17 | 0.0 |
p38 Mitogen-Activated Protein Kinases | 3 | 0.0 |
Acute Disease | 2 | 0.0 |
Analysis of Variance | 6 | 0.0 |
Disease Models, Animal | 4 | 0.0 |
Hamsters | 6 | 0.0 |
Research Support, Non-U.S. Gov't | 155 | 0.0 |
Serine Endopeptidases/*metabolism | 5 | 5.0 |
Child | 4 | 0.0 |
Thailand/epidemiology | 2 | 3.0 |
Antihypertensive Agents/pharmacology/therapeutic use | 2 | 66.0 |
English Abstract | 4 | 0.0 |
Inflammation/physiopathology | 2 | 3.0 |
Receptor, Angiotensin, Type 1 | 24 | 19.0 |
Receptors, Angiotensin/antagonists & inhibitors/*metabolism | 3 | 100.0 |
CHO Cells | 3 | 0.0 |
Cells, Cultured | 35 | 0.0 |
Hydrogen-Ion Concentration | 4 | 0.0 |
Immunohistochemistry | 9 | 0.0 |
Myocardium/*metabolism | 5 | 2.0 |
Nitric Oxide/metabolism | 3 | 1.0 |
Adolescent | 12 | 0.0 |
Adult | 92 | 0.0 |
Aldosterone/blood | 17 | 8.0 |
Angiotensin II/*pharmacology | 50 | 47.0 |
Angiotensinogen/*genetics | 7 | 7.0 |
Antihypertensive Agents/*pharmacology | 5 | 11.0 |
Genotype | 10 | 0.0 |
Middle Aged | 62 | 0.0 |
Models, Biological | 4 | 0.0 |
Benzimidazoles/*pharmacology | 3 | 13.0 |
Cross-Over Studies | 11 | 1.0 |
Double-Blind Method | 16 | 0.0 |
Forearm/*blood supply | 3 | 14.0 |
Imidazoles/pharmacology | 9 | 4.0 |
Pyridines/pharmacology | 5 | 1.0 |
Receptors, Angiotensin/*antagonists & inhibitors | 13 | 15.0 |
Regional Blood Flow/drug effects | 7 | 6.0 |
Tetrazoles/*pharmacology | 4 | 20.0 |
Vascular Resistance/drug effects | 2 | 3.0 |
Vasoconstrictor Agents/*pharmacology | 9 | 24.0 |
Administration, Oral | 2 | 0.0 |
Blood Pressure/drug effects | 32 | 5.0 |
Heart Rate/drug effects | 10 | 4.0 |
Hemodynamic Processes/*drug effects | 2 | 1.0 |
Aged, 80 and over | 7 | 0.0 |
Angiopoietin-1 | 4 | 5.0 |
Angiopoietin-2 | 3 | 5.0 |
Membrane Glycoproteins/genetics/metabolism | 2 | 2.0 |
Proteins/genetics/metabolism | 2 | 1.0 |
Survival Analysis | 6 | 0.0 |
Hypertension/*metabolism | 5 | 16.0 |
Kidney/*metabolism | 2 | 1.0 |
Receptors, Angiotensin/metabolism | 4 | 26.0 |
Angiotensin II/administration & dosage | 3 | 50.0 |
Glomerular Filtration Rate | 2 | 1.0 |
Sodium/metabolism | 3 | 2.0 |
Vasoconstrictor Agents/administration & dosage | 2 | 33.0 |
Angiotensin II/administration & dosage/*pharmacology | 5 | 71.0 |
Blood Vessels/*drug effects | 2 | 50.0 |
Brachial Artery | 2 | 18.0 |
Forearm/blood supply | 4 | 8.0 |
Injections, Intravenous | 2 | 0.0 |
Reference Values | 14 | 0.0 |
Angiotensin II/pharmacology | 12 | 16.0 |
Comparative Study | 34 | 0.0 |
Diet, Sodium-Restricted | 6 | 20.0 |
Feedback | 3 | 1.0 |
Hypertension/blood/physiopathology | 2 | 40.0 |
Renin/*blood | 2 | 2.0 |
Models, Molecular | 12 | 0.0 |
Protein Conformation | 6 | 0.0 |
Recombinant Proteins/chemistry/metabolism | 2 | 0.0 |
Ribonuclease, Pancreatic/*chemistry/metabolism | 2 | 100.0 |
Case-Control Studies | 3 | 0.0 |
Disease Progression | 9 | 0.0 |
Ribonuclease, Pancreatic/*blood | 5 | 55.0 |
Vascular Endothelial Growth Factor A | 5 | 0.0 |
Vascular Endothelial Growth Factors | 5 | 0.0 |
Angiotensin II/*metabolism/pharmacology | 3 | 50.0 |
Gene Expression/drug effects | 5 | 0.0 |
RNA, Messenger/metabolism | 7 | 0.0 |
Syndrome | 2 | 0.0 |
Infusions, Intravenous | 10 | 1.0 |
Renin-Angiotensin System/drug effects/physiology | 3 | 13.0 |
Sensitivity and Specificity | 3 | 0.0 |
Sodium, Dietary/*administration & dosage | 3 | 42.0 |
Adrenal Glands/metabolism | 2 | 4.0 |
Blood Pressure/physiology | 5 | 2.0 |
Mice | 19 | 0.0 |
Mice, Inbred C57BL | 8 | 0.0 |
Mice, Knockout | 6 | 0.0 |
*NADPH Oxidase | 3 | 7.0 |
Phosphoproteins/metabolism | 2 | 0.0 |
Sodium, Dietary/administration & dosage | 3 | 33.0 |
Endothelium, Vascular/*metabolism | 2 | 0.0 |
Enzyme Inhibitors/pharmacology | 13 | 0.0 |
Flavonoids/pharmacology | 2 | 0.0 |
Losartan/pharmacology | 13 | 40.0 |
RNA, Messenger/biosynthesis | 6 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 6 | 0.0 |
*Blood Pressure | 3 | 2.0 |
Diastole | 3 | 4.0 |
Systole | 5 | 5.0 |
Enzyme-Linked Immunosorbent Assay | 4 | 0.0 |
Mice, Inbred BALB C | 2 | 0.0 |
Angiotensin II/*physiology | 6 | 16.0 |
Kidney/*physiology | 3 | 7.0 |
Renin-Angiotensin System/physiology | 3 | 6.0 |
Collagen/metabolism | 2 | 0.0 |
Drug Interactions | 6 | 0.0 |
Phosphorylation/drug effects | 3 | 0.0 |
Tyrosine/metabolism | 2 | 0.0 |
Prospective Studies | 3 | 0.0 |
Statistics, Nonparametric | 2 | 0.0 |
Aging/metabolism | 2 | 1.0 |
Blood Pressure | 11 | 1.0 |
Glutathione/metabolism | 4 | 1.0 |
Rats, Inbred SHR | 4 | 4.0 |
Rats, Inbred WKY | 2 | 2.0 |
Angiotensin II/*biosynthesis | 4 | 26.0 |
Angiotensin-Converting Enzyme Inhibitors/pharmacology | 17 | 21.0 |
Angiotensinogen/metabolism | 2 | 40.0 |
Captopril/pharmacology | 6 | 10.0 |
Enzyme Activation/drug effects | 4 | 0.0 |
In Vitro | 21 | 0.0 |
Oligopeptides/pharmacology | 7 | 3.0 |
Peptidyl-Dipeptidase A/metabolism | 3 | 6.0 |
Recombinant Proteins/metabolism | 2 | 0.0 |
Substrate Specificity | 5 | 0.0 |
Vasoconstriction/drug effects | 3 | 8.0 |
Vasoconstrictor Agents/pharmacology | 6 | 16.0 |
Binding Sites | 12 | 0.0 |
Hydrogen Bonding | 5 | 2.0 |
COS Cells | 2 | 0.0 |
Kinetics | 17 | 0.0 |
Protein Structure, Tertiary | 4 | 0.0 |
Sequence Homology, Amino Acid | 4 | 0.0 |
Sodium Chloride/pharmacology | 3 | 3.0 |
Transfection | 6 | 0.0 |
Retrospective Studies | 2 | 0.0 |
Osmolar Concentration | 2 | 0.0 |
Receptors, Angiotensin/*physiology | 3 | 33.0 |
Aging | 2 | 0.0 |
European Continental Ancestry Group | 3 | 0.0 |
Lipoproteins, LDL Cholesterol/*blood | 2 | 2.0 |
Receptors, Angiotensin/*genetics | 3 | 6.0 |
Antihypertensive Agents/pharmacology | 14 | 28.0 |
Benzimidazoles/pharmacology | 4 | 9.0 |
Plasminogen Activator Inhibitor 1/*metabolism | 3 | 13.0 |
Tetrazoles/pharmacology | 11 | 28.0 |
Hypertrophy | 5 | 4.0 |
RNA, Messenger/genetics/metabolism | 4 | 0.0 |
Superoxides/*metabolism | 4 | 4.0 |
Aldosterone/*biosynthesis | 2 | 12.0 |
Base Sequence | 16 | 0.0 |
Blotting, Northern | 5 | 0.0 |
Cell Line | 13 | 0.0 |
DNA Primers | 4 | 0.0 |
RNA, Messenger/genetics | 2 | 0.0 |
Renin/blood | 18 | 5.0 |
*Proto-Oncogene Proteins | 2 | 0.0 |
Receptor, TIE-2 | 2 | 3.0 |
Tumor Cells, Cultured | 10 | 0.0 |
Angiotensin II/metabolism | 3 | 7.0 |
Vasodilation/drug effects | 3 | 5.0 |
Cell Movement/drug effects | 2 | 0.0 |
Receptors, Angiotensin/antagonists & inhibitors | 7 | 14.0 |
Dogs | 6 | 0.0 |
Lisinopril/pharmacology | 4 | 40.0 |
Potassium Chloride/pharmacology | 2 | 3.0 |
Serine Proteinase Inhibitors/pharmacology | 2 | 4.0 |
Species Specificity | 3 | 0.0 |
Vasoconstriction/*drug effects/physiology | 2 | 25.0 |
Losartan/*pharmacology | 2 | 25.0 |
Placebos | 4 | 1.0 |
Angiotensin II/physiology | 4 | 17.0 |
DNA-Binding Proteins/*metabolism | 2 | 0.0 |
Protein-Tyrosine Kinase/*metabolism | 2 | 0.0 |
Signal Transduction/*physiology | 3 | 0.0 |
Trans-Activators/metabolism | 2 | 0.0 |
Biphenyl Compounds/pharmacology | 6 | 22.0 |
Glomerular Filtration Rate/drug effects | 3 | 6.0 |
Glucose Clamp Technique | 3 | 2.0 |
Renal Circulation/drug effects | 9 | 28.0 |
Blotting, Western | 6 | 0.0 |
Infusions, Parenteral | 2 | 1.0 |
NADPH Oxidase/metabolism | 2 | 4.0 |
Phosphoproteins/*metabolism | 5 | 1.0 |
Superoxides/metabolism | 5 | 1.0 |
Angiotensin II/blood/*pharmacology | 3 | 50.0 |
Blood Pressure/drug effects/physiology | 3 | 7.0 |
Heart Rate/drug effects/physiology | 2 | 11.0 |
Organ Specificity | 4 | 0.0 |
*Polymorphism, Genetic | 4 | 0.0 |
Chromatography, Affinity | 5 | 0.0 |
Chromatography, Gel | 3 | 0.0 |
Chromatography, Ion Exchange | 2 | 0.0 |
Eosinophil Granule Proteins | 2 | 0.0 |
Reproducibility of Results | 2 | 0.0 |
Angiotensin II/*pharmacology/physiology | 3 | 50.0 |
Phenylephrine/pharmacology | 3 | 8.0 |
Animals, Genetically Modified | 4 | 1.0 |
NF-kappa B/metabolism | 3 | 0.0 |
Promoter Regions (Genetics)/genetics | 2 | 0.0 |
Transcription Factor AP-1/metabolism | 2 | 0.0 |
Angiotensin II/metabolism/*pharmacology | 3 | 50.0 |
Endothelium, Vascular/enzymology | 2 | 4.0 |
Peptidyl-Dipeptidase A/*metabolism | 5 | 5.0 |
Regional Blood Flow | 2 | 1.0 |
Regression Analysis | 3 | 0.0 |
Angiotensin II/pharmacology/*physiology | 3 | 37.0 |
Hemodynamic Processes | 3 | 1.0 |
Norepinephrine/pharmacology | 3 | 3.0 |
Sympathetic Nervous System/*physiopathology | 2 | 5.0 |
Angiotensin I/analysis | 2 | 100.0 |
Swine | 4 | 0.0 |
Vasoconstriction/*drug effects | 2 | 5.0 |
Potassium/pharmacology | 2 | 3.0 |
Mice, Transgenic | 3 | 0.0 |
Angiotensin II/*antagonists & inhibitors | 3 | 11.0 |
Rats, Wistar | 7 | 0.0 |
Reactive Oxygen Species/metabolism | 6 | 1.0 |
Albuminuria/chemically induced/drug therapy/immunology | 2 | 100.0 |
Angiotensin II/*adverse effects | 2 | 66.0 |
Enzyme Inhibitors/*pharmacology | 4 | 0.0 |
Genes, Reporter/genetics | 2 | 0.0 |
Muscle, Smooth, Vascular/drug effects/metabolism | 2 | 14.0 |
Mutagenesis, Site-Directed | 5 | 0.0 |
8-Bromo Cyclic Adenosine Monophosphate/pharmacology | 2 | 2.0 |
Antibodies, Monoclonal/pharmacology | 2 | 0.0 |
Cell Division/drug effects | 6 | 0.0 |
DNA/biosynthesis | 2 | 0.0 |
Protein Biosynthesis | 5 | 0.0 |
NADPH Oxidase/*metabolism | 3 | 7.0 |
Reverse Transcriptase Polymerase Chain Reaction | 6 | 0.0 |
Stimulation, Chemical | 3 | 0.0 |
Thrombin/pharmacology | 2 | 0.0 |
Umbilical Veins/cytology | 3 | 1.0 |
Angiotensin II/*blood | 3 | 11.0 |
Structure-Activity Relationship | 4 | 0.0 |
Angiotensins/biosynthesis/*genetics | 2 | 100.0 |
Cell Nucleus/metabolism | 3 | 0.0 |
Chloramphenicol O-Acetyltransferase/metabolism | 2 | 1.0 |
DNA-Binding Proteins/*genetics/*metabolism | 2 | 1.0 |
Gene Deletion | 2 | 0.0 |
*Gene Expression Regulation | 2 | 0.0 |
Liver/metabolism | 4 | 0.0 |
Mice, Inbred ICR | 2 | 0.0 |
Response Elements | 2 | 0.0 |
Transcription Factors/*genetics/*metabolism | 2 | 1.0 |
Transcription, Genetic | 4 | 0.0 |
Endothelium, Vascular/cytology/*drug effects | 2 | 2.0 |
Hypertension/*drug therapy/metabolism | 2 | 15.0 |
Intercellular Adhesion Molecule-1/*biosynthesis/genetics | 2 | 10.0 |
Umbilical Veins | 3 | 0.0 |
Ligands | 2 | 0.0 |
Binding, Competitive | 5 | 0.0 |
Fluorescent Antibody Technique | 2 | 0.0 |
Aldosterone/metabolism | 3 | 15.0 |
Renin/metabolism | 2 | 16.0 |
Endothelium, Vascular/cytology | 2 | 0.0 |
RNA, Messenger/analysis | 5 | 0.0 |
Angiotensin I/metabolism | 4 | 19.0 |
Macromolecular Substances | 2 | 0.0 |
Renin-Angiotensin System/*drug effects | 4 | 3.0 |
Prognosis | 5 | 0.0 |
*Protein Biosynthesis | 2 | 0.0 |
*Ribonuclease, Pancreatic | 12 | 70.0 |
Imidazoles/blood/*pharmacology | 2 | 100.0 |
Muscle Contraction/drug effects | 3 | 3.0 |
Rabbits | 10 | 0.0 |
Tetrazoles/blood/*pharmacology | 2 | 100.0 |
Angiotensin II Type 1 Receptor Blockers | 3 | 27.0 |
Endothelial Cells/*metabolism | 2 | 6.0 |
Genetic Markers | 2 | 0.0 |
Myocardium/pathology | 4 | 4.0 |
Organ Size/drug effects | 2 | 2.0 |
Oxidative Stress | 3 | 0.0 |
Acetylcholine/pharmacology | 3 | 4.0 |
Peptidyl-Dipeptidase A/*physiology | 3 | 37.0 |
Neoplasm Staging | 2 | 0.0 |
Apoptosis/*drug effects | 2 | 0.0 |
Saralasin/pharmacology | 4 | 50.0 |
In Situ Hybridization | 3 | 0.0 |
Up-Regulation | 3 | 0.0 |
Kidney/metabolism | 4 | 1.0 |
Phosphorylation | 4 | 0.0 |
Protein Transport | 2 | 0.0 |
Cell Division/physiology | 2 | 0.0 |
Hypertension/drug therapy/physiopathology | 2 | 12.0 |
Renin-Angiotensin System/*physiology | 7 | 12.0 |
Drug Synergism | 3 | 0.0 |
*Gene Expression Regulation, Neoplastic | 2 | 0.0 |
Mice, Nude | 2 | 0.0 |
Crystallography, X-Ray | 5 | 0.0 |
Eosinophil-Derived Neurotoxin | 2 | 2.0 |
Mutation/genetics | 2 | 0.0 |
Protein Structure, Secondary | 3 | 0.0 |
1-Sarcosine-8-Isoleucine Angiotensin II/pharmacology | 2 | 66.0 |
Vasoconstriction/drug effects/physiology | 2 | 18.0 |
Angiotensin II/*antagonists & inhibitors/pharmacology | 2 | 50.0 |
Blood Pressure/*drug effects | 11 | 7.0 |
Transduction, Genetic | 2 | 0.0 |
*Neovascularization, Pathologic | 3 | 0.0 |
Myocardium/*enzymology | 2 | 2.0 |
Cell Membrane/metabolism | 2 | 0.0 |
Half-Life | 2 | 0.0 |
Peptidyl-Dipeptidase A/*genetics | 3 | 0.0 |
Mitogen-Activated Protein Kinase 1/*metabolism | 2 | 1.0 |
Fibroblast Growth Factor 2/*blood | 2 | 3.0 |
Image Processing, Computer-Assisted | 2 | 0.0 |
Receptors, Angiotensin/*metabolism | 3 | 18.0 |
Angiotensin II/*therapeutic use | 2 | 66.0 |
Proteins/*metabolism | 3 | 0.0 |
Radioimmunoassay | 6 | 0.0 |
Angiotensin II/*genetics | 2 | 50.0 |
Thermodynamics | 2 | 0.0 |
Nitroprusside/pharmacology | 2 | 2.0 |
Alleles | 2 | 0.0 |
Angiotensin II/blood | 5 | 8.0 |
Heart Rate/*drug effects | 2 | 6.0 |
Biphenyl Compounds/*pharmacology | 3 | 20.0 |
Imidazoles/*pharmacology | 2 | 2.0 |
Kidney/*drug effects/physiology | 3 | 30.0 |
Losartan | 8 | 21.0 |
Computer Simulation | 3 | 0.0 |
Ribonucleases/*antagonists & inhibitors | 2 | 50.0 |
Angiotensin-Converting Enzyme Inhibitors/*pharmacology | 4 | 2.0 |
*Diet, Sodium-Restricted | 2 | 13.0 |
Enalapril/*pharmacology | 3 | 10.0 |
Hemodynamic Processes/drug effects | 7 | 4.0 |
DNA | 2 | 0.0 |
Promoter Regions (Genetics) | 2 | 0.0 |
Angiotensin II | 2 | 40.0 |
Crystallization | 2 | 0.0 |
Dinoprostone/biosynthesis | 2 | 3.0 |
Cattle | 9 | 0.0 |
Escherichia coli/genetics | 2 | 0.0 |
Cardiomegaly/pathology | 2 | 100.0 |
Kidney/pathology | 2 | 1.0 |
RNA, Messenger/*metabolism | 2 | 0.0 |
Chromatography, High Pressure Liquid | 5 | 0.0 |
Angiotensin II/metabolism/*physiology | 2 | 50.0 |
Angiotensin II/*administration & dosage | 3 | 50.0 |
*Renin-Angiotensin System | 2 | 7.0 |
Hormones/*blood | 2 | 1.0 |
Culture Media, Conditioned | 2 | 0.0 |
Angiotensin I/pharmacology | 2 | 18.0 |
Angiogenesis Inducing Agents/*metabolism | 2 | 7.0 |
Angiotensin-Converting Enzyme Inhibitors/*therapeutic use | 5 | 2.0 |
Antihypertensive Agents/*therapeutic use | 2 | 0.0 |
Polymerase Chain Reaction | 3 | 0.0 |
Cloning, Molecular | 3 | 0.0 |
Molecular Structure | 2 | 0.0 |
Receptors, Angiotensin/*analysis | 2 | 66.0 |
Electrophoresis, Polyacrylamide Gel | 2 | 0.0 |
Antihypertensive Agents/therapeutic use | 2 | 2.0 |
Hypertension/*drug therapy | 2 | 1.0 |
Tetrazoles/*therapeutic use | 2 | 13.0 |
Single-Blind Method | 5 | 2.0 |
Angiotensin II/blood/pharmacology | 2 | 100.0 |
Electrolytes/urine | 2 | 25.0 |
Infusions, Intra-Arterial | 2 | 3.0 |
Vasoconstrictor Agents/administration & dosage/*pharmacology | 2 | 66.0 |
Mitogen-Activated Protein Kinases/metabolism | 2 | 0.0 |
Insulin/*pharmacology | 2 | 0.0 |
Kidney/drug effects/*metabolism | 2 | 18.0 |
Heart Rate | 3 | 1.0 |
Potassium/blood | 2 | 2.0 |
Enalapril/pharmacology | 2 | 7.0 |
Cytosol/chemistry/drug effects | 2 | 66.0 |
Arteries | 2 | 3.0 |
Veins | 2 | 3.0 |
Perfusion | 2 | 0.0 |
Hypertension/*blood | 5 | 8.0 |
Indomethacin/pharmacology | 2 | 0.0 |
Aging/*physiology | 3 | 1.0 |
Blood Platelets/metabolism | 2 | 1.0 |
Autoradiography | 3 | 0.0 |
Binding Sites/drug effects | 2 | 3.0 |
Muscle, Smooth, Vascular/*drug effects | 2 | 10.0 |
Atrial Natriuretic Factor/*blood | 2 | 3.0 |
*Cardiovascular Physiology | 3 | 11.0 |
Sympathetic Nervous System/*physiology | 2 | 4.0 |
Aorta | 3 | 2.0 |
Hypertension/*drug therapy/physiopathology | 3 | 4.0 |
Renin/*antagonists & inhibitors | 2 | 22.0 |
Antibody Affinity | 2 | 1.0 |
Pregnancy | 3 | 0.0 |
Binding Sites/genetics | 2 | 0.0 |
Ribonuclease, Pancreatic/*antagonists & inhibitors/chemistry/*metabolism | 2 | 100.0 |
Calcium/metabolism | 2 | 0.0 |
Rats, Inbred Strains | 3 | 0.0 |
Restriction Mapping | 2 | 0.0 |
Biological Markers/blood/urine | 2 | 4.0 |
Angiotensin I/blood | 3 | 17.0 |
*Imidazoles | 2 | 25.0 |
Renin/*antagonists & inhibitors/*blood/pharmacology | 2 | 100.0 |
Animals, Newborn | 2 | 0.0 |
Molecular Weight | 2 | 0.0 |
Sequence Homology, Nucleic Acid | 2 | 0.0 |
Endothelium, Vascular/cytology/*drug effects/metabolism | 2 | 2.0 |
Chlorides/blood | 2 | 50.0 |
Age Factors | 2 | 0.0 |
Hypertension/*physiopathology | 3 | 4.0 |
Oxidative Stress/drug effects | 2 | 4.0 |
Angiotensin II/administration & dosage/blood | 2 | 100.0 |
Hypertension/blood/*drug therapy/physiopathology | 2 | 12.0 |
Renin-Angiotensin System/drug effects | 4 | 6.0 |
Atrial Natriuretic Factor/*pharmacology | 2 | 8.0 |
Angiotensin II/*cerebrospinal fluid | 3 | 100.0 |
Hypertension/*cerebrospinal fluid | 2 | 100.0 |
Peptidyl-Dipeptidase A/physiology | 2 | 13.0 |
Multivariate Analysis | 2 | 0.0 |
